LBA45 Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial
D. Schadendorf(West German Heart and Vascular Center Essen), E. Livingstone(Essen University Hospital), Rudolf Herbst(Helios Klinikum Erfurt), Christine Garbe(University of Tübingen), Anja Gesierich(University of Michigan), Alexander Roesch(Essen University Hospital), J.J. Grob(Hôpital Sainte-Marguerite), H. Gogas(National and Kapodistrian University of Athens), S. Ugurel-Becker(Ruhrlandklinik), P. Terheyden(University Hospital Schleswig-Holstein), Katharina C. Kähler(Christian-Albrechts-Universität zu Kiel), Željko Mijušković(Military Medical Academy), Friedegund Meier(National Center for Tumor Diseases), Thomas Eigentler(University Children's Hospital Tübingen), Dimitrios C. Ziogas(National and Kapodistrian University of Athens), Marlene Garzarolli, Lidija Kandolf Sekulović(Military Medical Academy), R. Gutzmer(LWL-Universitätsklinikum Bochum), Mirjana Ziemer(University Medical Center), L. Zimmer(Essen University Hospital)
Cited by 3
Related Papers
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k
Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
|The Lancet Oncology|2016|704
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells
|Cancer Cell|2013|680
Systematic Review of Medical Treatment in Melanoma: Current Status and Future Prospects
|The Oncologist|2011|579